Results 31 to 40 of about 9,092 (156)
Effect of bevacizumab assisted PD-1 inhibitor on serum miR-20a-5p and miR-515-3p in the treatment of gastric cancer [PDF]
Background and purpose: Second-line chemotherapy is not effective in the treatment of gastric cancer. Bevacizumab is a molecularly targeted anticancer drug, and sindilizumab is a domestic programmed death-1 (PD-1) inhibitor. The combination of the two is
WANG Fei, LIU Pei, HU Nan
core +1 more source
Zhongguo shiyan zhenduanxue, 2011 目的研究多肿瘤标志物蛋白芯片检测系统在消化道恶性肿瘤的普查、诊断及预后判断的临床价值。方法采用C-12蛋白芯片技术检测96例常见消化道恶性肿瘤患者组,87例消化道良性疾病患者组,120例健康查体者组血清中12项肿瘤标志物表达水平及阳性率,及51例消化道恶性肿瘤患者术后12项肿瘤标志物表达水平。结果消化道恶性肿瘤组肿瘤标志物C-12检测结果及阳性率明显高于良性疾病组及健康查体组,差异有显著性 ...
王晓飞, 王玉洁
doaj
Zhongguo shiyan zhenduanxue, 2012 目的探讨FOLFOX-4、XELOX和SOX三种化疗方法对晚期胃癌患者血清肿瘤标志物的影响。方法根据接受方案的不同分为FOLFOX-4、XELOX和SOX三种化疗组,采用ELISA法检测治疗前和治疗过程中TNF-α、CEA、CA72-4和CA19-9四种血清肿瘤标志物,并评定不良反应情况。结果 FOLFOX-4、XELOX和SOX三种化疗方法使血清肿瘤标志物表达水平下降,SOX组的TNF-α为(213.4±14.7)pg/ml,CEA为(15.0±1.9)μg/ml,CA72-4为(58.6±5.2)U/
郑晓可
doaj
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer [PDF]
Background and purpose: Despite the significant advancements that have been made in the treatment of gastric cancer, there are still problems such as poor prognosis and low five-year survival rate in advanced gastric cancer.
FENG Huizhi, LIU Jingmei, BU Xiaoqian
core +1 more source
Zhongguo shiyan zhenduanxue, 2008 目的研究多肿瘤标志物蛋白芯片检测系统在恶性肿瘤诊断与筛查中的应用价值。方法采用多肿瘤标志物蛋白芯片检测系统,检测98例恶性肿瘤患者,88例非肿瘤病人和99例健康体检者的12项常用肿瘤标志物,并与化学发光法进行比较分析。结果肿瘤组阳性率为71.4%、明显高于非肿瘤组（46.6%）和健康体检组（21.2%）（P0.05）;Fer、-βHCGf、-PSA、CA125在个别组有差异（0 ...
程建平, 张建明, 金跃
doaj
Establishment of discriminative models for predicting the infiltration degree of patients with lung adenocarcinoma based on clinical laboratory indicators [PDF]
Objective·To establish a multifactorial discriminative model for predicting the degree of infiltration in patients with non-small cell lung adenocarcinoma based on clinically accessible laboratory indicators, such as tumor markers, coagulation function ...
HUANG Lin +3 more
core +1 more source
细胞角蛋白19片段抗原21-1含量化学发光微粒子定量免疫检测方法的建立 [PDF]
, 2018 目的建立细胞角蛋白19片段抗原21-1(cytokeratin 19 fragment 21-1,CYFRA21-1,简称CY21-1)含量的化学发光微粒子免疫检测方法(chemiluminescent microparticle immunoassay,CMIA)。方法原核表达制备重组CY21-1(r CY21-1),用其免疫BALB/c小鼠后,收集小鼠脾脏细胞,常规杂交瘤技术与Sp2/0进行融合,制备CY21-1单抗。间接ELISA法筛选可稳定分泌CY21-1抗体的杂交瘤细胞,分别标记微性磁珠 ...
刘江武 +5 more
core +1 more source
CEA、Cyfra21-1、NSE、Ca50联合检测在肺癌中诊断价值
Zhongguo shiyan zhenduanxue, 2007 目的探讨肿瘤标志物CEA、Cyfra21-1、NSE、Ca50联合检测在肺癌中诊断价值。方法应用电化学发光免疫分析及免疫放射分析法对214例肺癌、28例良性病变、32例健康人测定血清肿瘤标志物水平。结果214例肺癌血清肿瘤标志物CEA、Cyfra21-1、NSE、Ca50水平高于良性病变、健康组 ...
陈武, 刘洋, 范艳红, 贺贵福
doaj
Application of the Flow Cytometric Bead-based Assay on the Detection of Tumor Markers in Clinical Samples [PDF]
, 2010 流式微珠分析技术是近年来发展起来的一种可以对多项指标同时进行定性、定量分析的新型检测技术。此技术将类似细胞大小的微珠作为反应载体，流式细胞仪作为检测平台。反应在悬浮液相中进行，有利于核酸、蛋白及其它生物大分子保持天然构象与活性，保证了检测反应的有效性。作为一种新兴的检测技术，流式微珠分析技术具有灵活性强、通量高、反应速度快、检测效率高、特异性好、灵敏度高、重现性好、动态检测范围宽、检测成本低等优点。 肿瘤标志物在肿瘤的临床诊断和治疗中占有重要的地位，通过对血液、体液中肿瘤标志物存在或含量的检测 ...
龙瑶
core
Zhongguo shiyan zhenduanxue, 2014 目的观察和分析应用癌胚抗原（CEA）、糖链抗原199（CA199）、CA242、CA724等血清肿瘤标志物联检对胃癌进行早期诊断的临床应用效果。方法选取80例胃癌患者作为观察组,选取同期慢性萎缩性胃炎伴重度不典型增生50例作为CAGD组,选取同期胃粘膜检查正常或浅表性胃炎者50例作为对照组,对三组研究对象的血清肿瘤标志物CA199、CA242、CA724、CEA水平进行检测和比较。结果观察组患者的血清CA199、CA242、CA724、CEA水平均显著高于CAGD组 ...
徐明星, 李曼, 彭波, 侯炜
doaj